Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 16 Jan 2023

FOXO3 gene hypermethylation and its marked downregulation in breast cancer cases: A study on female patients

in Cancer Molecular Targets and Therapeutics

Mohammad Aasif Khan
Sadaf
Irfan Ahmad
Abdulaziz A. Aloliqi
Alaa Abdulaziz Eisa
Mohammad Zeeshan Najm
Maria Habib
Saad Mustafa
Sheersh Massey
Zoya Malik

Frontiers in Oncology

doi 10.3389/fonc.2022.1078051

3,040 views
5 citations

Review

Published on 13 Jan 2023

Crosstalk between microwave ablation and ferroptosis: The next hot topic?

in Cancer Molecular Targets and Therapeutics

Lu Yu
Min Cheng
Jie Liu
Xin Ye
Zhigang Wei
Jiamei Xu
Qi Xie
Jing Liang

Frontiers in Oncology

doi 10.3389/fonc.2023.1099731

3,483 views
7 citations

Original Research

Published on 13 Jan 2023

Evaluating the local expression pattern of IGF-1R in tumor tissues and the circulating levels of IGF-1, IGFBP-1, and IGFBP-3 in the blood of patients with different primary bone tumors

in Cancer Molecular Targets and Therapeutics

Mohammad Amin Vaezi
Amir Reza Eghtedari
Banafsheh Safizadeh
Pegah Babaheidarian
Vahid Salimi
Fatemeh Adjaminezhad-Fard
Sahar Yarahmadi
Alireza Mirzaei
Mahtab Rahbar
Masoumeh Tavakoli-Yaraki

Frontiers in Oncology

doi 10.3389/fonc.2022.1096438

2,484 views
5 citations

Case Report

Published on 12 Jan 2023

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review

in Cancer Molecular Targets and Therapeutics

Yuri Isaka
Akinori Sasaki
Akira Saito
Yasuaki Motomura
Yayoi Ando
Yoshiaki Nakamura

Frontiers in Oncology

doi 10.3389/fonc.2022.1064944

1,568 views
1 citation

Original Research

Published on 12 Jan 2023

Development of anoikis-related genes signature to predict the prognosis in gastric cancer patients

in Cancer Molecular Targets and Therapeutics

Jie Cao
Kai Hong
Yuepeng Cao
Kenan Cen
Yifeng Mai
Ying Dai
Guifang Ouyang
Qitian Mu
Yangyang Guo

Frontiers in Oncology

doi 10.3389/fonc.2022.1096608

4,048 views
14 citations

Case Report

Published on 10 Jan 2023

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib

in Cancer Molecular Targets and Therapeutics

Wen-Chi Wu
Ming-Huang Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.1031396

1,841 views
1 citation

Brief Research Report

Published on 10 Jan 2023

Mild oxidative stress protects against chemotherapy-induced hair loss

in Cancer Molecular Targets and Therapeutics

Yusheng Zhang
Joaquin J. Jimenez

Frontiers in Oncology

doi 10.3389/fonc.2022.1078916

2,928 views
2 citations

Review

Published on 10 Jan 2023

Potassium channels: Novel targets for tumor diagnosis and chemoresistance

in Cancer Molecular Targets and Therapeutics

Meizeng Li
Peijie Tian
Qing Zhao
Xialin Ma
Yunxiang Zhang

Frontiers in Oncology

doi 10.3389/fonc.2022.1074469

5,642 views
22 citations

Review

Published on 09 Jan 2023

CircCCDC66: Emerging roles and potential clinical values in malignant tumors

in Cancer Molecular Targets and Therapeutics

Xiaoxiao Wang
Chao Zhang
Huangqin Song
Junlong Yuan
Lei Zhang
Jiefeng He

Frontiers in Oncology

doi 10.3389/fonc.2022.1061007

3,350 views
5 citations

Correction

Published on 06 Jan 2023

Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

in Cancer Molecular Targets and Therapeutics

Sunisa Prasopporn
Orawan Suppramote
Ben Ponvilawan
Chanette Jamyuang
Jantappapa Chanthercrob
Amphun Chaiboonchoe
Pimkanya More-Krong
Kamonchanok Kongsri
Monthira Suntiparpluacha
Rawisak Chanwat

Frontiers in Oncology

doi 10.3389/fonc.2022.1124912

1,263 views

Review

Published on 06 Jan 2023

Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening

in Cancer Molecular Targets and Therapeutics

Cuiying Xie
Ancheng Gu
Muhammad Khan
Xiangcao Yao
Leping Chen
Jiali He
Fumiao Yuan
Ping Wang
Yufan Yang
Yerong Wei

Frontiers in Oncology

doi 10.3389/fonc.2022.1105454

4,075 views
7 citations

Systematic Review

Published on 05 Jan 2023

Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis

in Cancer Molecular Targets and Therapeutics

Peizhuo Yao
Yinbin Zhang
Shuqun Zhang
Xinyu Wei
Yanbin Liu
Chong Du
Mingyou Hu
Cong Feng
Jia Li
Fang Zhao

Frontiers in Oncology

doi 10.3389/fonc.2022.1039882

6,093 views
11 citations

Original Research

Published on 04 Jan 2023

Crosstalk between protein kinases AKT and ERK1/2 in human lung tumor-derived cell models

in Cancer Molecular Targets and Therapeutics

Aurimas Stulpinas
Matas Sereika
Aida Vitkeviciene
Ausra Imbrasaite
Natalija Krestnikova
Audrone V. Kalvelyte

Frontiers in Oncology

doi 10.3389/fonc.2022.1045521

3,661 views
8 citations

Original Research

Published on 04 Jan 2023

A pan-cancer landscape of IGF2BPs and their association with prognosis, stemness and tumor immune microenvironment

in Cancer Molecular Targets and Therapeutics

Wei Shao
Hui Zhao
Shoudu Zhang
Qian Ding
Yugang Guo
Kaiqi Hou
Yunchao Kan
Fan Deng
Qian Xu

Frontiers in Oncology

doi 10.3389/fonc.2022.1049183

4,284 views
12 citations

Brief Research Report

Published on 23 Dec 2022

Multi-analyte liquid biopsies for molecular pathway guided personalized treatment selection in advanced refractory cancers: A clinical utility pilot study

in Cancer Molecular Targets and Therapeutics

Darshana Patil
Dadasaheb Akolkar
Rajnish Nagarkar
Navin Srivastava
Vineet Datta
Sanket Patil
Sachin Apurwa
Ajay Srinivasan
Rajan Datar

Frontiers in Oncology

doi 10.3389/fonc.2022.972322

2,244 views
3 citations

Original Research

Published on 23 Dec 2022

Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

in Cancer Molecular Targets and Therapeutics

Yezhe Cheng
Xiaoxi Yuan
Qiang Tian
Xiuying Huang
Yang Chen
Yuzhi Pu
Hu Long
Mingyu Xu
Yafei Ji
Jia Xie

Frontiers in Oncology

doi 10.3389/fonc.2022.951589

31,770 views
35 citations

Navigation group

Articles

FOXO3 gene hypermethylation and its marked downregulation in breast cancer cases: A study on female patients

Crosstalk between microwave ablation and ferroptosis: The next hot topic?

Evaluating the local expression pattern of IGF-1R in tumor tissues and the circulating levels of IGF-1, IGFBP-1, and IGFBP-3 in the blood of patients with different primary bone tumors

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review

Development of anoikis-related genes signature to predict the prognosis in gastric cancer patients

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib

Mild oxidative stress protects against chemotherapy-induced hair loss

Potassium channels: Novel targets for tumor diagnosis and chemoresistance

CircCCDC66: Emerging roles and potential clinical values in malignant tumors

Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening

Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis

Crosstalk between protein kinases AKT and ERK1/2 in human lung tumor-derived cell models

A pan-cancer landscape of IGF2BPs and their association with prognosis, stemness and tumor immune microenvironment

Multi-analyte liquid biopsies for molecular pathway guided personalized treatment selection in advanced refractory cancers: A clinical utility pilot study

Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132